ProtoKinetix PKTX

ProtoKinetix, Incorporated is a research and development stage bio technology company focused on scientific medical research of Anti Freeze Glycoproteins or anti aging glycoproteins trademarked as AAGPs. The company was originally incorporated as RJV Network Inc. under the laws of the State of Nevada on December 23 1999 to develop an internet based listing site for commercial real estate. In July 2003 it entered into an assignment of license agreement with BioKinetix Research Incorporated for rights to proprietary technologies related to superantibodies and changed its name to ProtoKinetix Incorporated. Its executive offices are located at 109 W Main St Dalton Ohio 44618.

ProtoKinetix Incorporated has not yet generated significant revenue from its operations. The company is in the research and development phase and incurs expenses related to the development and testing of the AAGP molecule. For the fiscal year ended December 31 2023 research and development expenses were $112 444 and for the fiscal year ended December 31 2024 they were $99 625. Funding for these activities is obtained through capital raising efforts.

ProtoKinetix Incorporated occupies a niche position in the biotechnology sector focusing on the therapeutic and preservation applications of Anti Freeze Glycoproteins. Its competitive advantage lies in the proprietary AAGP technology and the associated intellectual property rights. The company aims to differentiate itself by targeting large market opportunities such as cell preservation for transplantation anti aging treatments and diabetes related therapies. While specific competitor names are not disclosed in the filing the broader biotech field includes firms engaged in protein based therapeutics and cryopreservation solutions.

ProtoKinetix Incorporated collaborates with researchers business leaders advisors and commercial entities to advance the development and commercialization of AAGP. These partners include academic institutions private companies and potential strategic partners in the health care and biotechnology industries. The filing does not disclose specific customer names but indicates that the company seeks to engage entities interested in utilizing its glycoprotein technology for medical and industrial applications.